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Abstract. A 33-year-old female was diagnosed with a solid 
pseudopapillary tumor (SPT) of the pancreas and multiple liver 
metastases at the Department of Gastroenterological Surgery, 
Ishikawa Prefectural Central Hospital (Kanazawa, Japan). Distal 
pancreatectomy and postoperative systemic chemotherapy 
with gemcitabine (GEM) and S-1, an oral fluoropyrimidine 
derivative, was administered, however, liver metastases became 
enlarged and local recurrence occurred. Therefore, the patient 
was referred to the Department of Gastroenterologic Surgery at 
the Graduate School of Medicine (Kanazawa, Japan) for hepatic 
arterial infusion (HAI) chemotherapy. Oral S-1 (80 mg/m2) 
was administered as well as HAI chemotherapy with GEM 
(1,000 mg/standard liver volume). Following 18 cycles, tumor 
sizes were reduced and 18‑fluorodeoxyglucose positron emis-
sion tomography (18FDG‑PET) examination revealed obvious 
reduction of tumor FDG uptake. Transarterial tumor emboli-
zation (TAE) was performed for the previously unresectable 
right subphrenic liver tumor, and the other tumors were surgi-
cally resected. The resected tumors were diagnosed as liver 
metastases and a local recurrence of SPT in the postoperative 
pathological examination, which revealed that the resected 
tumors were composed of sheets of bland cells, which were 
positive for CD10, CD56, vimentin, neuron‑specific enolase 
and α-antitrypsin. The postoperative course was uneventful, 
and the patient is currently under observation at an outpatient 
clinic; postoperative adjuvant chemotherapy with oral S-1 
has continued, and additional TAE is planned. In the future, 
if the middle segment of the liver becomes enlarged, surgery 
for the residual right lobe tumor may be possible. This case 
demonstrates one method of SPT treatment: Preoperative HAI 
chemotherapy with GEM, plus oral S-1 and TAE. If complete 
resection can be achieved, the majority of patients with SPT 
have a favorable prognosis. In patients with unresectable metas-
tases from SPT, it is crucial to conduct systematic multimodal 
treatment to maximize treatment success.
Introduction
Solid pseudopapillary tumor (SPT) is a rare, nonfunctional 
neoplasm of the pancreas that occurs most frequently in 
young females with a mean age of 25 years (90% of all cases 
occur in female patients) (1). The first case was reported 
by Frantz in 1959 (2). The tumor may occur anywhere in 
the pancreas, however, is most frequently identified in the 
pancreatic body and tail. Histopathologically, SPT is clas-
sically defined as a large and encapsulated mass composed 
of a mixture of cystic and solid areas. Intratumoral hemor-
rhage is frequent, and calcifications have been reported in 
≤30% of cases (3-5). Although SPT is considered to be an 
indolent lesion with low malignant potential and a favorable 
prognosis following surgical resection, a number of cases of 
locally infiltrating and metastatic varieties, and post‑surgical 
recurrences have been reported (1). In 1996, the World Health 
Organization renamed the tumor as SPT and reclassified it as 
a low-grade malignant tumor (6). The incidence of SPT is 
low, accounting for 1‑2% of exocrine pancreatic tumors and 
5% of cystic pancreatic neoplasms.
The current study reports a case of SPT with multiple 
liver metastases and local recurrence following distal 
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pancreatectomy for the original lesion; the patient was 
treated with hepatic arterial infusion (HAI) chemotherapy, 
systemic chemotherapy, transarterial embolization (TAE), 
and surgical resection. Written informed consent was obtained 
from the patient.
Case report
A 33-year-old female was admitted to the Department of 
Gastroenterological Surgery, Ishikawa Prefectural Central 
Hospital (Kanazawa, Japan) in December 2006 with 
abdominal pain and vomiting. A cystic lesion of 10 cm in 
diameter was detected in the tail of the pancreas as well as 
multiple liver tumors using abdominal computed tomography 
(CT) (Fig. 1). In January 2007, distal pancreatectomy was 
performed at Ishikawa Prefectural Central Hospital. The 
pancreatic tumor was diagnosed as SPT on postoperative 
pathological examination, which revealed that the resected 
tumors were composed of sheets of bland cells with oval to 
round nuclei and a focal pseudopapillary appearance. Further-
more, immunohistochemical analysis revealed positivity for 
CD10, CD56, vimentin, neuron‑specific enolase (NSE) and 
α-antitrypsin. The multiple liver tumors were hypothesized to 
be SPT metastases. Following surgery, systemic chemotherapy 
with gemcitabine (GEM) and S‑1, an oral fluoropyrimidine 
derivative, was administered. However, the liver metastases 
gradually enlarged, and the patient was referred to the Depart-
ment of Gastroenterologic Surgery at the Graduate School 
of Medicine (Kanazawa, Japan) for hepatic arterial infusion 
(HAI) chemotherapy in September 2011.
Physical examination identified palpable hard masses 
of >10 cm  in diameter around the umbilical area and right 
lower quadrant. Abdominal contrast-enhanced CT revealed 
multiple heterogeneous solid and cystic tumors in the liver, and 
a large tumor of 15 cm  in diameter was identified in the left 
subphrenic area, indicating local recurrence following distal 
pancreatectomy (Fig. 2A). The lateral segment of the liver was 
infiltrated with tumors (Fig. 2B), and the 15‑cm diameter tumor 
had been growing suspended from the posterior segment of the 
liver (Fig. 2C). Additionally, large tumors were identified in the 
right subphrenic area in the anteroposterior segment of the liver. 
Complete surgical resection of the tumors was considered to be 
impossible, as the tumors were located in close proximity to the 
major Glisson sheath (Fig. 2A). Examination with 18‑fluorode-
oxyglucose positron emission tomography (FDG‑PET) revealed 
all of the tumors to have high FDG uptake, with maximum 
standardized uptake values (SUV max) of 7.7‑8.8 (Fig. 3A).
As it was impossible to treat the subphrenic local recurrent 
tumor with HAI chemotherapy, systemic chemotherapy was 
used in combination. In October 2011, oral S-1 (80 mg/m2) and 
HAI with GEM (1,000 mg/standard liver volume) were initi-
ated as described in a previous report (7). Following 18 cycles 
of HAI chemotherapy, the tumors exhibited a 26.3% reduction 
in size (Fig. 2D-F). Although this result was determined to be 
stable disease according to the Response Evaluation Criteria in 
Solid Tumors guidelines (8), FDG‑PET examination revealed 
obvious reduction of tumoral FDG uptake, and the SUV max 
was 5.4 in the lesion with the highest uptake (Fig. 3B).
While chemotherapy was effective, a complete resection 
was not predicted to be successful in this situation, due to 
the involvement of the major Glisson sheath. For the right 
subphrenic tumor, transcatheter arterial embolization (TAE) 
was a viable treatment. However, TAE was likely to cause the 
other tumors to rupture due to post-treatment necrosis. There-
fore, TAE was performed for the unresectable right subphrenic 
liver tumor occupying the anteroposterior segment, and the 
other tumors were surgically resected once the patient's condi-
tion stabilized post-TAE.
The resected tumors were diagnosed as liver metastases 
and a local recurrence of SPT on postoperative pathological 
examination. The tumor specimen was a highly vascular 
lesion composed of sheets of bland cells with oval to round 
nuclei, moderate cytoplasm, ill‑defined cell borders, and a 
focal pseudopapillary appearance (Fig. 4A). On immunohisto-
chemical analysis, the tumor cells reacted positively for CD10, 
CD56, vimentin, NSE, and α-antitrypsin, however, the Ki-67 
index was low (1‑2%; Fig. 4B‑H). Electron microscopy was 
performed to characterize the nature of the cytoplasmic vacu-
oles that appeared to be dilated or distended mitochondria; 
the remaining fractions appeared to be smooth endoplasmic 
reticulum, consistent with a previous report (Fig. 5). In a 
number of the small vacuoles, a few cristae could still be 
identified as mitochondrial, and a gradual transition from the 
normal mitochondria to those with attenuation of cristae was 
observed as well as loss of matrix.
The postoperative course was uneventful, and the patient 
is currently under monthly observation at an outpatient clinic 
and receiving adjuvant chemotherapy with oral S-1 (100 mg, 
every other day).
Discussion
SPTs of the pancreas are uncommon low-malignant epithelial 
tumors that are typically identified in adolescent females. 
Metastatic disease is rare and only occurs in around 10-15% 
of patients (9-11). Previous studies have indicated the most 
frequently observed metastatic sites to be the liver and 
omentum (12). Resection of the primary pancreatic tumors or 
liver metastases has yielded excellent survival with an overall 
cure rate of >90%  (13-16). The clinical features of SPT are 
Figure 1. Abdominal computed tomography image following previous hos-
pital admission. A cystic tumor of 10 cm  in diameter in the pancreatic tail 
(with calcification) and multiple liver tumors were detected.
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non‑specific and are often caused by compression from the 
tumor. Abdominal pain or discomfort is the most common 
symptom, followed by back pain, nausea, vomiting, weight 
loss, and diarrhea (1). A number of patients present with 
jaundice, upper gastrointestinal bleeding, or other rare symp-
toms; however, a considerable number of patients exhibit no 
symptoms, and SPT is identified incidentally during physical 
examination or on ultrasound, CT, or other imaging examina-
tions (1). Although resection of the tumor yields a five‑year 
survival rate of 97%, local recurrence or distant metastases 
occur in 10-15% of patients (1).
The primary morphological differential diagnosis for 
SPT is pancreatic neuroendocrine tumor. Traditionally, 
negative staining for neuroendocrine markers, in particular 
chromogranin A, has been considered crucial to this distinc-
tion. However, a recent study demonstrated aberrant nuclear 
staining for β‑catenin and a loss of membranous expression of 
E-cadherin with aberrant nuclear localization of the cytoplasmic 
domain in all pancreatic SPT cases analyzed (17). In this study, 
the majority of pancreatic SPTs were also strongly positive for 
vimentin (100%), β-catenin nuclear stain (100%), CD10 (96%), 
progesterone receptor (79%), CD56 (75%), cytokeratin (28%), 
synapthophysin (26%), and chromogranin A (15%) (17). In the 
present case, CD10, CD56, and vimentin were strongly positive.
At present, no consistent clinical or histological criteria 
has been established to predict the biological behavior of SPT. 
Invasion of blood vessels, peritoneal infiltration, invasion of 
adjacent structures, a high degree of cellular polymorphism, 
and an elevated mitotic rate are characteristics proposed 
to be associated with metastases and recurrence. However, 
the absence of these features does not preclude malignant 
behavior. In the present case, the patient exhibited multiple 
liver metastases at initial presentation in the absence of malig-
nant histological behavior.
Figure 2. Abdominal CT images pre- and post-chemotherapy. (A)  Abdominal CT showed recurrence of the local tumor following distal pancreatectomy in 
the form of a large tumor (15 cm  in diameter) in the left subphrenic area, as well as liver metastases in the left lateral segment and anteroposterior segment. 
(B) The left lateral segment was occupied by a tumor, which was palpable in the upper abdomen. (C) A large mass of the lower posterior segment was palpable 
in the right lower quadrant of the abdomen. (D-F) Following combination therapy with gemcitabine hepatic arterial infusion, plus oral S-1 and transarterial 
embolization of the anteroposterior segment, the recurrent local tumor was slightly reduced in size and the liver metastases were obviously reduced. CT, 
computed tomography.
Figure 3. FDG‑PET analysis. (A) Extremely high FDG uptake by the tumors was detected on FDG‑PET analysis. (B) Following chemotherapy and transarte-
rial embolization, a reduction of FDG uptake was observed. FDG‑PET, 18‑fluorodeoxyglucose‑positron emission tomography. 
  A   B
  A   B   C
  D   E   F
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The current study demonstrates that SPT is an indolent 
tumor with an excellent prognosis and that surgical resec-
tion is the mainstay of treatment, even in the presence of 
local invasion and extrapancreatic involvement. Indeed, 
involvement of the surgical margins (R1) does not appear to 
be associated with a poor outcome. In previously reported 
studies, ≤20% of the cases have exhibited liver metastases at 
the time of resection, however, the overall five‑year survival 
rate remains >95% (11). In the present patient, as the liver 
metastases were diffuse, radical excision of these metastases 
was not possible. Therefore, combination therapy with TAE 
and chemotherapy was selected for treatment of the remnant 
liver tumor.
The value of chemotherapy for patients with SPT remains 
unknown, however, a number of anecdotal studies have 
reported its benefit (13,18‑20) and lack of benefit (9,21,22). 
Figure 4. Histological features and immunohistochemical characteristics of the tumor. (A) Histological features include pseudopapillary architecture with 
fibrovascular stalks and small, uniform tumor cells with round nuclei. The tumor was characterized by positive staining for (B) α-antitrypsin, (C) CD56, 
(D) vimentin, and (E) NSE; and by weak staining for (F) chromogranin A and (G) synapthophysin. (H) The Ki‑67 index was low (1‑2%).
Figure 5. Electron microscopy: Dilated mitochondria and small vacuoles 
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Two cases involving resectable tumors were subjected to 
chemotherapy with cisplatin and 5‑fluorouracil (5‑FU) (19) 
or GEM (20), but in the latter case, previous treatment with 
5-FU and radiation had failed to decrease the tumor size. 
Radiotherapy is occasionally used for the treatment of unre-
sectable tumors or as an adjuvant treatment following tumor 
resection (13). Two cases of radiosensitivity in unresectable 
tumors have been reported (23,24). Kanter et al reported the 
advantages of neoadjuvant chemotherapy with GEM for a 
large SPT (25). In another report, a patient who presented 
with a large SPT arising from the pancreatic body and tail 
(with gastric wall infiltration and para-aortic lymphade-
nopathy) was treated with GEM and cisplatin. During this 
therapy, the tumor regressed by >50%, with disappearance 
of the para-aortic lymphadenopathy and posterior gastric 
wall infiltration; the patient subsequently underwent full 
surgical resection (26).
In the current patient, oral S-1 and HAI with GEM were 
administered, which resulted in the reduction of tumor size 
on CT and an obvious reduction of FDG uptake on FDG-PET 
analysis. It was originally proposed that S-1 and GEM had 
been invalidated as treatment options based on their ineffec-
tive use at the previous hospital, however, it is possible that 
a sufficient amount had not been administered due to patient 
complaints and side effects. In the Department of Gastro-
enterologic Surgery at the Graduate School of Medicine, 
combination treatment with oral S-1 and HAI using GEM 
was effective. However, there is a possibility that oral S-1 
administration alone was effective in treating the local recur-
rence at the left diaphragm, which was not reached by the 
arterial infusion of GEM but nonetheless decreased slightly 
in size. Therefore, oral S-1 was used for postoperative adju-
vant chemotherapy.
Transarterial tumor embolization and transcatheter 
arterial chemoembolization are seldom used to treat SPT or 
similar pancreatic neoplasms (21,22,27). Among previous 
cases, one patient experienced a significant reduction in 
metastases of the right lobe (21), one succumbed to the 
disease following the procedure (27), and one patient's 
disease remained unchanged (22). Radiofrequency ablation 
(RFA) is also a seldom-used modality (22,28,29). RFA is a 
safe and effective treatment for multiple unresectable liver 
metastases of SPT (29). However, incomplete RFA may 
induce dedifferentiation and epithelial-mesenchymal transi-
tion of the tumor (30,31). Therefore, it is advisable to limit 
the use of RFA to unresectable and small lesions.
In the current study, TAE was performed for residual liver 
tumors prior to surgical resection. Oral S-1 was subsequently 
administered as postoperative chemotherapy, and additional 
TAE is planned. In the future, if the central region of the 
liver enlarges, surgery for the residual right lobe tumor may 
become possible.
In conclusion, this case demonstrates one method of treat-
ment for SPT: Preoperative chemotherapy with GEM HAI in 
combination with oral S-1 and TAE. If complete resection 
can be achieved, the majority of patients with SPT have a 
favorable prognosis. In patients with unresectable metastases 
from SPT, it is crucial to perform systematic multimodal 
treatment, with a combination of surgery, chemotherapy and 
interventional radiology, to maximize treatment success.
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